Navigation Links
Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
Date:10/23/2007

LONDON, Oct. 23 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, today announced the initiation of a Phase I tolerance study of MRX-4 in 16 patients suffering from allergic rhinitis (AR).

The randomized, placebo-controlled, double blind clinical trial is the first of two modules focusing on safety for Morria's first human study in AR. MRX-4 is nasally administered as a single dose either with or without an allergen challenge to determine tolerance. Results are expected by the end of the fourth quarter of 2007.

"We are excited to be taking this significant step toward introducing a potentially safer, more effective and more affordable treatment option to the multibillion-dollar AR market," said Yuval Cohen Ph.D., President of Morria.

"There is a real and urgent need for novel, non-steroidal treatments for inflammatory diseases such as allergic rhinitis. Morria's drug platform could potentially offer such an alternative," said Peter Barnes, a professor at the National Heart & Lung Institute at Imperial College in London and Morria scientific advisory board member.

ABOUT ALLERGIC RHINITIS

Allergic rhinitis is a common condition that affects nearly 59 million people in the United States (nearly 20 percent of the population) with a market of nearly $4 billion. Allergic rhinitis is characterized by inflammation of the nasal membranes accompanied by symptoms that may include sneezing, nasal congestion, nasal itching and rhinorrhea.

ABOUT MORRIA BIOPHARMACEUTICALS Plc

Morria Biopharmaceuticals Plc is a biopharmaceutical company focused on the development of novel anti-inflammatory pharmaceuticals known as multi-functional anti-inflammatory drugs (MFAIDs). This class of drugs uniquely combines two promising approaches to preventing and reversing inflammation: first, they control the phospholipase A2 (PLA2) enzyme family, a known but previous
'/>"/>

SOURCE Morria Biopharmaceuticals Plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
3. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
6. Malvern initiates European user group meetings for chemical imaging
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , 2 de julio de 2015 BGI ... ADN de alto rendimiento en Hong ... College of Pathologists (CAP). La instalación de BGI en ... de secuenciación de próxima generación que recibe la certificación ... más alto estándar en prácticas de laboratorio clínico. Junto ...
(Date:7/2/2015)... Ill. , July 2, 2015  AbbVie (NYSE: ... results on Friday, July 24, 2015, before the market ... of the earnings conference call at 8 a.m. Central ... AbbVie,s Investor Relations website at www.abbvieinvestor.com . An ... 11 a.m. Central time. About AbbVie ...
(Date:7/2/2015)... BioLife Solutions , Inc. (NASDAQ: BLFS ), a leading ... tissue hypothermic storage and cryopreservation freeze ... management app for smart shippers ("BioLife" or ... has included BioLife in its annual list of the 100 ... for 2015. Now in its 24th ...
Breaking Medicine Technology:BGI recibe la acreditación del College of American Pathologists (CAP) 2BioLife Solutions Named One of the 100 Best Companies to Work For in Washington State 2BioLife Solutions Named One of the 100 Best Companies to Work For in Washington State 3
... 16 Metabolic Solutions Development Company (MSDC), www.msdrx.com ... the Study of Diabetes (EASD) annual conference in Stockholm, ... the company,s clinical candidate, MSDC-0160, promotes the proliferation of ... creation of more brown fat.  The research was conducted ...
... LOS ANGELES, Sept. 16 Canon Communications LLC ... United Business Media Limited, a leading global business ... LLC , the management/investment company of Canon Chairman and CEO ... private equity partner.  Apprise and Spectrum acquired Canon in 2005. ...
Cached Medicine Technology:Metabolic Solutions Development Company to Present Research Findings to European Association for the Study of Diabetes 2Canon Communications to be Sold to United Business Media; Transaction Expands Global Reach of Canon's Advanced Manufacturing and Design Focus 2Canon Communications to be Sold to United Business Media; Transaction Expands Global Reach of Canon's Advanced Manufacturing and Design Focus 3
(Date:7/3/2015)... , ... July 03, 2015 , ... ... took place on June 25, 2015 at 1:00pm. The Association welcomed speaker C. ... pertaining to injured bicyclists and practical points of investigating these types of cases. ...
(Date:7/3/2015)... ... July 03, 2015 , ... First Choice Emergency ... named Mariah N. Manzanares, MD as the new Medical Director of its Frisco facility. ... director of our Frisco facility,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... The Celebrity ... or cocktail dresses similar to those of celebrities will have the opportunity to get ... at checkout. This ensures that people do not have to use coupon codes or ...
(Date:7/2/2015)... ... , ... Following the recent report by JAMA Internal Medicine published ... Americans, Samir Becic emphatically declared a war on obesity in the United States. , ... "We must understand the magnitude of this discovery. For that reason, I am declaring, ...
(Date:7/2/2015)... ... ... With summer in full swing, Americans are flocking to Canada’s many lakes to reel in ... in the world, and it’s easy to understand why. From the Pacific Northwest Coast of ... Recreational fishing is a huge industry, and Americans make up the vast majority of anglers ...
Breaking Medicine News(10 mins):Health News:Attorney from William Mattar Leads Discussion on Bicycle Accidents 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3Health News:Celebrity Fashion Summer Party Dresses on sale at TheCelebrityDresses.com 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4
... nuggets after the introduction of a single gene from ... a valuable tool for tracking cells, movement through the ... PhD, professor of biomedical engineering at Emory University and ... a very simple way to make mammalian cells have ...
... their genetic make-up, study says , , TUESDAY, June 3 ... habit may have a lot to do with your ... have found gene patterns that influence a smoker,s response ... variations that appear to indicate the likelihood of success ...
... 2007 was its,17th consecutive year of growth and ... care insurance industry for,the last five years with ... 2007), MedAmerica Insurance Company of New York ... Pittsburgh, PA), and MedAmerica,Insurance Company of Florida (Home ...
... Istrodent as Exclusive Dental Distributor of the STA(TM) System in ... ... June 3 Milestone Scientific,Inc. (OTC Bulletin Board: MLSS), the recognized ... a,leading South African distributor of dental products to professional dental,practitioners, has ...
... 2008 the Philadelphia,Physicians for Student Athletics (PPSA) will ... School District. Student,athletes in Pennsylvania are required to ... interscholastic activities. The standard physicals are a good,step ... some potentially,life-threatening conditions., The 2008 program will ...
... round of Critical Challenges in,Parkinson,s Disease initiative, ... Fox,Foundation for Parkinson,s Research is committing up to ... that would allow,scientists to visualize pathological clumping of ... techniques hold potential to,serve as critically needed biomarkers ...
Cached Medicine News:Health News:Genes May Play Role in Quitting Smoking 2Health News:Genes May Play Role in Quitting Smoking 3Health News:Milestone Scientific Expands Global Distribution Network 2Health News:Milestone Scientific Expands Global Distribution Network 3Health News:Philly's Top Doc's Organize to Help Prevent Young Athlete Deaths in Philadelphia 2Health News:Michael J. Fox Foundation for Parkinson's Research Commits up to $2 million to Visualize Alpha-Synuclein Protein in the Brain 2Health News:Michael J. Fox Foundation for Parkinson's Research Commits up to $2 million to Visualize Alpha-Synuclein Protein in the Brain 3
... is designed to provide rapid atraumatic stone ... NCircle combines traditional surgical instrument design with ... technology. The small, flexible wire design ... surgeon to remove larger stones or stone ...
... Used for temporary internal drainage from ... Supplied sterile in peel-open packages. Intended ... is advised; C-Flex® and Sof-Flex® stents ... six (6) months; silicone stents must ...
... ACMI™ Classic Double Pigtail Ureteral ... pigtail design that maximizes migration. They ... added versatility and cost savings. Each ... contains one Classic Double PigTail Ureteral ...
The Needle Loading Platform / Shield is designed to provide superior operator shielding during the loading of prostate implant needles with iodine or palladium seeds. It is constructed of 3/8" alumin...
Medicine Products: